US 11,939,389 B2
BCMA chimeric antigen receptors and uses thereof
Aida Abujoub, Winchester, MA (US); John Blankenship, Acton, MA (US); Dexiu Bu, Melrose, MA (US); Tony Fleming, Stow, MA (US); Brian Holmberg, Somerville, MA (US); Connie Hong, Somerville, MA (US); Lu Huang, West Roxbury, MA (US); and Chonghui Zhang, Cambridge, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Feb. 17, 2023, as Appl. No. 18/170,969.
Application 18/170,969 is a division of application No. 16/439,495, filed on Jun. 12, 2019, granted, now 11,608,382.
Claims priority of provisional application 62/832,991, filed on Apr. 12, 2019.
Claims priority of provisional application 62/684,628, filed on Jun. 13, 2018.
Prior Publication US 2023/0183368 A1, Jun. 15, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 90 Claims
 
1. A method of providing an anti-tumor immunity in a subject having BCMA-expressing cancer cells, the method comprising administering to the subject an effective amount of cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain comprising a primary signaling domain and a costimulatory signaling domain, wherein:
(a) the anti-BCMA binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO: 86, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO: 87, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 88, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO: 95, a light chain complementarity determining region 2 (LC CDR2) of SEQ ID NO: 96, and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 97;
(b) the primary signaling domain comprises:
(i) a functional signaling domain of CD3 zeta or FcR gamma; or
(ii) an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 9 or 10; and
(c) the costimulatory signaling domain comprises:
(i) a functional signaling domain of 4-1BB (CD137), OX40, CD2, CD27, CD28, ICAM-1, LFA-1, or ICOS (CD278); or
(ii) an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 7.